Bicara Therapeutics Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Bicara Therapeutics Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$155.60M	-$82.39M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$137.95M	-$68.00M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.00	$-4.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.00	$-4.00

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$96.69M	$489.70M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$430.99M	$510.00M
Everything the company owes — debt, unpaid bills, and other obligations.	$29.54M	$18.12M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$401.45M	$491.88M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$106.83M	-$74.75M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$280000	$71000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$107.11M	-$74.82M